1986-90,
McGill University Faculty of Medicine, Canada, B.Sc.,
Biochemistry
1990-93,
University of Montreal, Canada, Other, Biochemistry
1993-98, University of Ottawa, Canada, Ph.D.,
Biochemistry
Residencies
Fellowships
1997-01,
J. David Gladstone Institutes, Postdoctoral Fellow, Mouse Models of
Human Disease
2001-04, J. David Gladstone Institutes, Postdoctoral
Fellow, Mouse Models of Human Disease
Postdoctoral Training
Board Certification
Program Affiliations
Clinical Expertise
Research Interests
Website LInks
Biography
Research Summary
Selected Publications
Raffai RL, Dong LM, Farese RV, Weisgraber KH. Introduction of
human apolipoprotein E4 "domain interaction" into mouse
apolipoprotein E. Proc Natl Acad Sci U S A. 98: 11587-91,
Sep/25/2001.
Raffai RL, Weisgraber KH. Hypomorphic apolipoprotein E mice: a
new model of conditional gene repair to examine apolipoprotein
E-mediated metabolism. J Biol Chem. 277: 11064-8, Mar/29/2002.
Raffaï RL, Hasty AH, Wang Y, Mettler SE, Sanan DA, Linton
MF, Fazio S, Weisgraber KH. Hepatocyte-derived ApoE is more
effective than non-hepatocyte-derived ApoE in remnant lipoprotein
clearance. J Biol Chem. 278: 11670-5, Mar/28/2003.
Raffai RL, Loeb SM, Weisgraber KH. Apolipoprotein E promotes
the regression of atherosclerosis independently of lowering plasma
cholesterol levels. Arterioscler Thromb Vasc Biol. 25: 436-41,
Feb/2005.
Zhang S, Picard MH, Vasile E, Zhu Y, Raffai RL, Weisgraber KH,
Krieger M. Diet-induced occlusive coronary atherosclerosis,
myocardial infarction, cardiac dysfunction, and premature death in
scavenger receptor class B type I-deficient, hypomorphic
apolipoprotein ER61 mice. Circulation. 111: 3457-64,
Jun/28/2005.